Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ITOS

ITeos Therapeutics Inc

Dec 13 • 04:00PM ET

7.68

Dollar change -0.27
Percentage change -3.34	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM XBI VXF IWN DFAT IBB SCHA VTWO DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.15	Insider Own	15.79%	Shs Outstand	36.53M	Perf Week	-7.69%
Market Cap	271.22M	Forward P/E	-	EPS next Y	-3.92	Insider Trans	0.09%	Shs Float	30.76M	Perf Month	-13.02%
Income	-121.25M	PEG	-	EPS next Q	-1.03	Inst Own	86.85%	Short Float	6.38%	Perf Quarter	-36.53%
Sales	35.00M	P/S	7.75	EPS this Y	-1.40%	Inst Trans	2.77%	Short Ratio	2.86	Perf Half Y	-52.68%
Book/sh	17.29	P/B	0.44	EPS next Y	-22.73%	ROA	-17.31%	Short Interest	1.96M	Perf Year	-30.05%
Cash/sh	13.84	P/C	0.55	EPS next 5Y	-	ROE	-19.72%	52W Range	7.54 - 18.75	Perf YTD	-29.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-40.62%	ROI	-19.07%	52W High	-59.04%	Beta	1.37
Dividend TTM	-	Quick Ratio	14.80	Sales past 5Y	-23.53%	Gross Margin	96.72%	52W Low	1.86%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	14.80	EPS Y/Y TTM	-83.02%	Oper. Margin	-429.55%	RSI (14)	34.85	Volatility	5.05% 5.18%
Employees	157	Debt/Eq	0.01	Sales Y/Y TTM	-47.37%	Profit Margin	-346.44%	Recom	1.00	Target Price	23.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-16.70%	Payout	-	Rel Volume	0.96	Prev Close	7.95
Sales Surprise	-	EPS Surprise	10.36%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	685.08K	Price	7.68
SMA20	-6.23%	SMA50	-12.43%	SMA200	-40.42%	Trades		Volume	658,406	Change	-3.34%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
01:01AM	Loading…
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Loading…
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	Loading…
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%
04:01PM	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jun-30-22 08:41AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
May-16-22 06:27AM	Forecast: Analysts Think iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) Business Prospects Have Improved Drastically (Simply Wall St.)
May-12-22 05:45PM	ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-11-22 04:09PM	Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer (Investor's Business Daily) -29.77%
07:03AM	Recent 8.9% pullback isn't enough to hurt long-term iTeos Therapeutics (NASDAQ:ITOS) shareholders, they're still up 13% over 1 year (Simply Wall St.)
Apr-08-22 01:00PM	iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022 (GlobeNewswire)
Mar-26-22 02:51PM	Analysts Just Slashed Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) EPS Numbers (Simply Wall St.)
Mar-23-22 05:55PM	ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-22 07:00AM	iTeos to Present at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 07:55AM	5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates (Zacks) +5.79%
Feb-10-22 07:00AM	iTeos to Participate in Upcoming Investor Conferences in February (GlobeNewswire)
Feb-01-22 09:38AM	Jackson Creek Investment Advisors LLC Buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART ... (GuruFocus.com)
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... (GuruFocus.com)
Jan-10-22 07:00AM	iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Jan-03-22 04:46PM	Why iTeos Therapeutics Topped the Market Today (Motley Fool) -11.49%
04:01PM	iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ITOS

ITeos Therapeutics Inc

Upgrade your FINVIZ experience